Masahiro Kiuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Masahiro Kiuchi has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Kiyoshi Hirahara
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
38 shared publications - Toshinori Nakayama
Department of Immunology, Graduate School of Medicine Chiba University Chiba Japan
36 shared publications - Motoko Y. Kimura
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan
35 shared publications - Ami Aoki
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
34 shared publications - Atsushi Onodera
Institute for Advanced Academic Research, Chiba University, Chiba, Japan
34 shared publications - Shinichiro Motohashi
Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
33 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
Open AccessCD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 11 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6778) , eadp0714
Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 + T cells
CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.
- 11 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6778) , eadp0714
Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 + T cells
CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadp0849
Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity
A unique subpopulation of memory T helper 2 (T H 2) cells expressing the interleukin-33 (IL-33) receptor ST2 drives allergic disease pathogenesis. However, the immunometabolic mechanisms that induce ST2 hi memory T H 2 cells remain unclear. We show using a mouse model of chronic allergic airway inflammation that long-chain unsaturated fatty acids (LC-UFAs) accumulate in the inflammatory milieu during chronic airway inflammation. Activated T H 2 cells take up LC-UFAs, transiently store them in lipid droplets (LDs), and catabolize LDs through lipolysis and microlipophagy. LD catabolism regulated by adipose triglyceride lipase (ATGL) activates peroxisome proliferator–activated receptor γ (PPARγ). PPARγ then binds the Il1rl1 locus encoding ST2 and induces ST2 hi effector and memory T H 2 cells. In eosinophilic chronic rhinosinusitis, CD45RO + CD4 T cells in nasal polyps exhibit microlipophagy and an accessible IL1RL1 enhancer, indicating that these mechanisms are conserved in humans. Thus, the storage and catabolism of inflammatory milieu–derived LC-UFAs direct pathogenic adaptive type 2 immunity, offering potential therapeutic strategies for persistent allergic inflammation.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadp0849
Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity
A unique subpopulation of memory T helper 2 (T H 2) cells expressing the interleukin-33 (IL-33) receptor ST2 drives allergic disease pathogenesis. However, the immunometabolic mechanisms that induce ST2 hi memory T H 2 cells remain unclear. We show using a mouse model of chronic allergic airway inflammation that long-chain unsaturated fatty acids (LC-UFAs) accumulate in the inflammatory milieu during chronic airway inflammation. Activated T H 2 cells take up LC-UFAs, transiently store them in lipid droplets (LDs), and catabolize LDs through lipolysis and microlipophagy. LD catabolism regulated by adipose triglyceride lipase (ATGL) activates peroxisome proliferator–activated receptor γ (PPARγ). PPARγ then binds the Il1rl1 locus encoding ST2 and induces ST2 hi effector and memory T H 2 cells. In eosinophilic chronic rhinosinusitis, CD45RO + CD4 T cells in nasal polyps exhibit microlipophagy and an accessible IL1RL1 enhancer, indicating that these mechanisms are conserved in humans. Thus, the storage and catabolism of inflammatory milieu–derived LC-UFAs direct pathogenic adaptive type 2 immunity, offering potential therapeutic strategies for persistent allergic inflammation.
- Open Access
- 31 July 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (1) , 105-119
Increased expression of the PIEZO2 mechanoreceptor in fibroblasts and endothelial cells within the lymphatic and vascular vessels of keloids
Keloids are scars that grow abnormally due to excessive extracellular matrix production by fibroblasts and increased angiogenesis. Chronic tension is implicated in their growth, but the exact pathology remains unclear. This study investigated the increased expression of molecules responsible for sensing pressure in keloids compared with lymphedema, which is also a non‐tumorous fibroproliferative disease caused by another etiology. Higher expression levels of COL1A2 , PIEZO2 , and POSTN were observed in the keloid group compared with the lymphedema group. PIEZO2 expression levels showed a strong correlation with both COL1A2 ( r = 0.9252, 95% CI 0.8474–0.9641, p < 0.001) and POSTN ( r = 0.9118, 95% CI 0.8213–0.9575, p < 0.001). Additionally, PIEZO2 expression levels were significantly higher in recurrent keloids than in non‐recurrent keloids (3,032.5 ± 1,090.2 versus 1,241.9 ± 860.7, p = 0.032). Analysis of gene expression at the single‐cell level found upregulation of PIEZO2 in vascular and lymphatic endothelial cells, and a subgroup of fibroblasts. Additionally, COL1A1 , COL1A2 , COL3A1 , and POSTN expression was also increased in the fibroblast subgroup. Furthermore, in fibroblasts with high PIEZO2 expression, extracellular matrix collagen production signaling was augmented. Histological analysis confirmed the presence of PIEZO2‐positive cells in the perivascular stroma active area of keloid tissue, together with inflammatory cells. Therefore, since PIEZO2‐positive cells are highly expressed specifically in keloids and are deeply involved in their recurrence and activity, we propose that the pathogenesis of keloids is constructed by PIEZO2‐positive cells. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 31 July 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (1) , 105-119
Open AccessIncreased expression of the PIEZO2 mechanoreceptor in fibroblasts and endothelial cells within the lymphatic and vascular vessels of keloids
Keloids are scars that grow abnormally due to excessive extracellular matrix production by fibroblasts and increased angiogenesis. Chronic tension is implicated in their growth, but the exact pathology remains unclear. This study investigated the increased expression of molecules responsible for sensing pressure in keloids compared with lymphedema, which is also a non‐tumorous fibroproliferative disease caused by another etiology. Higher expression levels of COL1A2 , PIEZO2 , and POSTN were observed in the keloid group compared with the lymphedema group. PIEZO2 expression levels showed a strong correlation with both COL1A2 ( r = 0.9252, 95% CI 0.8474–0.9641, p < 0.001) and POSTN ( r = 0.9118, 95% CI 0.8213–0.9575, p < 0.001). Additionally, PIEZO2 expression levels were significantly higher in recurrent keloids than in non‐recurrent keloids (3,032.5 ± 1,090.2 versus 1,241.9 ± 860.7, p = 0.032). Analysis of gene expression at the single‐cell level found upregulation of PIEZO2 in vascular and lymphatic endothelial cells, and a subgroup of fibroblasts. Additionally, COL1A1 , COL1A2 , COL3A1 , and POSTN expression was also increased in the fibroblast subgroup. Furthermore, in fibroblasts with high PIEZO2 expression, extracellular matrix collagen production signaling was augmented. Histological analysis confirmed the presence of PIEZO2‐positive cells in the perivascular stroma active area of keloid tissue, together with inflammatory cells. Therefore, since PIEZO2‐positive cells are highly expressed specifically in keloids and are deeply involved in their recurrence and activity, we propose that the pathogenesis of keloids is constructed by PIEZO2‐positive cells. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes